Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.


NIH GUIDE, Volume 23, Number 39, November 4, 1994


P.T. 34


  Clinical Trial 

  Fungal Diseases+ 

National Institute of Allergy and Infectious Diseases

The Bacteriology and Mycology Branch, Division of Microbiology and

Infectious Diseases of the National Institute of Allergy and

Infectious Diseases (NIAID) has a requirement for a collaborative

clinical trials group for serious fungal infections to include those

caused by Candida, Aspergillus, Cryptococcus, Coccidioides,

Histoplasma, and Blastomyces.  A clinical trials program will be

designed to facilitate advances in antifungal therapy by rigorously

determining the efficacy and safety of new therapeutic regimens for

serious mycotic diseases.  The program will be driven by a scientific

agenda with proposed studies that will address the most important

gaps in treatment, the appropriate fungal pathogens and risk groups.

Risk groups of emphasis are HIV infected patients, neutropenic cancer

patients, bone marrow and organ transplant patients, and surgical

trauma patients.  Provision should also be made for the key

management problems with the endemic mycoses in immunocompetent


This group will conduct Phase II and Phase III clinical trials to

evaluate antifungal therapies including, but not limited to new

agents, formulations, dosing regimens, drug combinations, as well as

immunebased therapeutics.

Request for Proposals (RFP) No. NIH-NIAID-DMID-96-04 will be

available on or about November 15, 1994.  Responses will be due at

close of business February 15, 1995.  It is anticipated that one,

cost reimbursement, completion contract will be awarded for a period

of five years.  All interested offerors are encouraged to submit a

proposal.  Any responsible offeror may submit a proposal that will be

considered by the Government.


To receive a copy of the RFP, supply this office with two self-

addressed mailing labels.  Telephone inquiries will not be honored

and all inquiries must be in writing and addressed to:

Mr. Anthony J. Murray

Contract Management Branch

National Institute of Allergy and Infectious Diseases

6003 Executive Boulevard MSC 7610

Solar Building, Room 3C07

Bethesda, MD  20892-7610

Interested organizations should request either a streamlined or full

RFP package.  If no selection is made, a streamlined version of the

RFP will be provided, which includes only the Statement of Work,

deliverable and reporting requirements, special requirements and

mandatory qualifications, if any, and the Technical Evaluation

Criteria.  After examination of the abbreviated document, any

organization interested in responding to the RFP must request the

entire RFP in writing or by FAX request (301) 480-5253.  This

advertisement does not commit the Government to award a contract.


Return to 1994 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.